FDA Approves Vegzelma (bevacizumab-adcd), a Biosimilar to Avastin

Vegzelma is Celltrion’s third oncology biosimilar to receive approval from the U.S. FDA Vegzelma offers U.S. patients living with multiple types of cancer a new, safe, and effective treatment option The approval is based on totality of...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news